An overview of biospecimens collected at baseline from individuals within the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD)
| Crohn’s disease n=142 | Ulcerative colitis n=201 | IBD-unclassified n=24 | Symptomatic control n=168 | Healthy control n=59 | |
| Serum, n (%) | 137 (96) | 199 (99) | 23 (96) | 164 (98) | 59 (100) |
| Faecal, n (%)* | 99 (70) | 137 (68) | 20 (83) | 112 (67) | 56 (95) |
| Intestinal biopsies, n (%) | 92 (65) | 161 (80) | 18 (75) | 155 (92) | 58 (98) |
| Urine, n (%) | 62 (44) | 91 (45) | 9 (38) | 90 (54) | 58 (98) |
*Faecal samples for microbiome analyses and for additional faecal marker. Samples for faecal calprotectin were handled separately.
IBD, inflammatory bowel disease.